Antibody Drug Conjugate News and Research

RSS

Seattle Genetics commences phase I clinical trial of SGN-75 ADC for metastatic renal cell carcinoma

Seattle Genetics, Inc. today announced that it has initiated a phase I clinical trial of SGN-75 for metastatic renal cell carcinoma and relapsed and refractory non-Hodgkin lymphoma. SGN-75 is an antibody-drug conjugate (ADC) targeting CD70 that utilizes the company’s proprietary technology.

16 Nov 2009

Affiliated Dialysis Centers to purchase nursing home dialysis business in Chicago

Affiliated Dialysis Centers, LLC (“ADC”), an independent dialysis provider based in Illinois, today announced that a definitive agreement has been reached to purchase a nursing home dialysis business in the Chicago market.

3 Nov 2009

Seattle Genetics reports its third-quarter financial results

Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2009. The company also highlighted recent product development progress.

24 Oct 2009

UTAS chooses ADI Blackfin processors to ensure high quality patient care

Analog Devices, Inc. (NYSE: ADI) today announced that UTAS, a provider of medical devices for patient monitoring and diagnostics, has selected ADI Blackfin® processors to ensure high-performance digital signal processing operations and robust functionality across its full line of products.

28 Sep 2009

SEA technology to increase potency of monoclonal antibodies

Seattle Genetics, Inc. announced today the introduction of its sugar engineered antibody (SEA) technology, a novel approach to increasing the potency of monoclonal antibodies through enhanced effector function. The technology will be presented today by Dennis Benjamin, Ph.D., Senior Director, Chemistry, during the Americas Antibody Congress being held in Washington, DC.

23 Sep 2009

Bayer submits an IND for its MN-IC antibody-drug conjugate to the FDA

Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration with Bayer Schering Pharma AG, Germany. The milestone was triggered by Bayer’s submission of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for MN-IC, an ADC for solid tumors.

9 Sep 2009

Seattle Genetics completes enrollment of its pivotal clinical trial of brentuximab vedotin

Seattle Genetics, Inc. today announced that it has completed enrollment of its pivotal clinical trial of brentuximab vedotin (SGN-35) for relapsed and refractory Hodgkin lymphoma. Brentuximab vedotin is an antibody-drug conjugate (ADC) targeted to CD30 utilizing the company’s proprietary ADC technology.

25 Aug 2009

Bioheart's executive management team strengthened by the inclusion of board members

Bioheart, Inc., (OTC Bulletin Board: BHRT) a company committed to delivering intelligent devices and biologics that help monitor, diagnose and treat heart failure and other cardiovascular diseases announced today that several of its Directors have joined the Company's executive management team. In addition to assuming the position of Chairman of the Company's Board of Directors, Karl E. Groth, Ph.D., became the Chief Executive Officer; Peggy A. Farley became Chief Operating Officer; and Mark P. Borman became Chief Financial Officer. Howard Leonhardt will continue as Chief Scientific and Technology Officer, and Chairman of the Scientific Advisory Board. Mr. Leonhardt, the Company's founder, thus will be able to focus on enhancing the Company's existing technologies and strengthening its position as the leader within the cardiovascular arena of the stem cell therapy industry.

19 Aug 2009

Seattle Genetics reaches milestone under collaboration agreement with MedImmune

Seattle Genetics, Inc. (NASDAQ:SGEN), announced today that it has achieved a milestone under its antibody-drug conjugate (ADC) collaboration agreement with MedImmune, LLC, a wholly owned subsidiary of AstraZeneca. The milestone was triggered by MedImmune’s initiation of a phase I clinical trial of MEDI-547, its anti-EphA2 ADC for solid tumors.

11 Aug 2009

Seattle Genetics starts Brentuximab Vedotin retreatment trial

Seattle Genetics, Inc. has announced that it has initiated a phase II clinical trial of brentuximab vedotin (SGN-35), an antibody-drug conjugate (ADC), for the retreatment of patients with Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL).

27 Jul 2009

Seattle Genetics starts trial of SGN-35 for anaplastic large cell lymphoma

Seattle Genetics, Inc. (NASDAQ:SGEN), has announced that it has initiated a phase II clinical trial of SGN-35 for patients with relapsed or refractory systemic anaplastic large cell lymphoma (ALCL). SGN-35 is an antibody-drug conjugate (ADC) that utilizes Seattle Genetics’ proprietary technology to empower antibodies by linking them to potent cell-killing drugs.

18 Jun 2009

Few food adverts during children's TV are likely to be banned under new regulations

Advertisements shown during children's television before new restrictive regulations were introduced were not any more focused on unhealthy food than adverts shown at other times, according to research published ahead of print in the Archives of Disease in Childhood.

27 May 2009

Music played to premature babies may help to reduce their pain and improve feeding habits

Music played to premature babies may help to reduce their pain and encourage better oral feeding, suggests research published ahead of print in the Archives of Disease in Childhood.

27 May 2009

Seattle Genetics presents new data on antibody-drug conjugate

Seattle Genetics, Inc. has announced that data from its antibody-drug conjugate (ADC) programs, SGN-35 and SGN-75, were presented at the 2009 Annual Meeting of the American Association for Cancer Research (AACR) being held in Denver, CO. Preclinical data with SGN-35 further elucidate its mechanism of action and demonstrate its superior antitumor activity in lymphoma compared with non-targeted agents. In addition, data with SGN-75 indicate its therapeutic potential in multiple types of solid tumors.

22 Apr 2009

Medarex announces allowance of IND application for antibody-drug conjugate, MDX-1203

Medarex, Inc. has announced the allowance of an investigational new drug (IND) application filed with the U.S. Food & Drug Administration (FDA) for MDX-1203, the Company's first Antibody-Drug Conjugate (ADC) candidate generated from its proprietary technology.

29 Jan 2009